Sanofi-AgaMatrix Deal a Harbinger
Executive Summary
Sanofi-Aventis is allying with AgaMatrix around the latter's blood glucose monitoring technology. The deal gets Sanofi a BGM product line and access to a technology around which it can begin to build an integrated diabetes management system. Importantly, it signals to other companies that it is moving in that direction. That could help Sanofi in partnering or M&A discussions around other aspects of diabetes device development, including continuous glucose monitoring, and also stimulate competitors to pick up the deal-making pace.
You may also be interested in...
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.
Merck Adds To Diabetes Franchise With SmartCells Acquisition
Merck announced Dec.2 that it is acquiring privately-held SmartCells for the company's preclinical SmartInsulin diabetes program in a deal potentially worth as much as $500 million. The acquisition will help bolster sales of Merck's blockbuster diabetes drug Januvia.